Table 1.

Characteristics, treatments, and outcomes of patients with lichen planopilaris treated with oral tofacitinib

Patient #	Sex	Disease duration (years)	Type/biopsy proven	Prior treatmentsattempted	Daily tofacitinib dose (mg)	Treatment duration (months)	Concurrent therapies
1	M	6	Patchy	Topical steroids, intralesional triamcinolone, minoxidil, excimer laser, hydroxychloroquine, pioglitazone, prednisone	15	10	Intralesional triamcinolone
2	M	15	Patchy	Pioglitazone, mycophenolic acid	10	17
3	M	1	Diffuse/yes	Topical steroids, intralesional triamcinolone, doxycycline, excimer laser, prednisone, hydroxychloroquine, pioglitazone, finasteride	10	3
4	F	2	FFA	Topical steroids, intralesional triamcinolone, doxycycline, hydroxychloroquine	10	9	Intralesional triamcinolone
5	F	1	FFA/yes	Topical steroids, minoxidil, excimer laser, doxycycline, hydroxychloroquine, finasteride	10	6	Intralesional triamcinolone, hydroxychloroquine
6	F	10	Patchy	Topical steroids, minocycline, finasteride	10	7	Tacrolimus ointment, intralesional triamcinolone
7	F	2	Patchy	Intralesional triamcinolone	15	19
8	M	1	Patchy/yes	Topical steroids, doxycycline, hydroxychloroquine, pioglitazone, finasteride, mycophenolic acid	10	16	Hydroxychloroquine
9	F	1	Patchy/yes	Intralesional triamcinolone, doxycycline, finasteride	10	10
10	F	2	Diffuse/yes	Topical steroids, doxycycline	10	2

Patient #	LPPAI pre‐treatment	LPPAI post‐treatment	% changeLPPAI	Notes
1	5.33	1.42	−73
2	5.58	1.75	−68
3	7.5	7.5	0	No improvement
4	6.67	4.58	−32
5	5.667	0.333	−94
6	Not assessed	–	–	No improvement
7	Not assessed	–	–	Flared after stoppingtofacitinib
8	6.67	2.08	−69
9	6	4.25	−30
10	6.33	2.75	−5

Abbreviation: LPPAI = lichen planopilaris activity index.